GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bio Green Med Solution BGMS · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.83

-3.86%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Bio Green Med Solution

From its filings with the US Securities and Exchange Commission

SEC filings

Bio Green Med Solution is based in Berkeley Heights, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BGMS. The SEC classifies its business as wholesale-durable goods, nec. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $3.0m. At that date it held total assets of $8.2m and shareholders' equity of $6.8m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
1 Jan 1996
Employees
12
Head office
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ, 07922
Incorporated in
DE
Classification
Wholesale-Durable Goods, NEC
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Datuk Sing Ee WongChief Executive Officer, Executive Director, since 2025
  • Mr. Cu Seng KiuChief Financial Officer, Executive Director, Company Secretary, since 2025
  • Ms. Inigo LaurduraIndependent Director
  • Dr. Satis Waran Nair KrishnanIndependent Director
  • Ms. Soon Ping PappasIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Cyclacel Pharmaceuticals has 12 full-time employees in Berkeley Heights.
  • Sapacitabine is an orally available nucleoside analog for anticancer treatment.
  • Seliciclib is a lead CDK inhibitor targeting CDK2/9 enzymes for cell division control.

Weaknesses

  • Cyclacel has no clinical stage drugs beyond sapacitabine and CYC065.
  • The company's business relies on a single sector: Health Care.
  • Cyclacel's employees are limited to 12 full-time staff in one location.

Opportunities

  • Cyclacel can expand its drug portfolio with nucleoside analogs like gemcitabine.
  • The company can leverage CDK inhibitors for hematological malignancies and solid tumors.
  • Cyclacel may develop new applications for Aurora Kinase/VEGFR inhibitors.

Threats

  • Cyclacel faces competition from generic drugs such as gemcitabine and cytarabine.
  • The company's reliance on a single industry sector increases vulnerability.
  • Cyclacel's small employee count may limit research and development capacity.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.